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 “The importance of integrating medication adherence in 
pharmacoeconomic analyses: the example of osteoporosis”
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Cost-effectiveness analysis
 Data from phase III clinical trials
⇒ cost-effectiveness of intervention/drug in clinical trial
 Data from phase IV (post-marketing)
⇒ cost-effectiveness of intervention/drug in the community
 Clinical effectiveness versus efficacy: poor compliance and 
failure to persist
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Medication compliance and persistence
 Poor and suboptimal in chronic diseases
 ↓ treatment effectiveness
 Impact on healthcare costs (↓ therapy costs, ↑ disease costs)
⇒ May have an impact on cost-effectiveness
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Definitions and measurement
Compliance (synonym ‘adherence’): “the extent to 
which a patient acts in accordance with the prescribed 
interval and dose of a dosing regimen”
Persistence “the duration of time from initiation to 
discontinuation of therapy”
Cramer et al. Value Health 2008;11:44-47
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Definition
Cramer et al. Value Health 2008;11:44-47
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Measurement
 Medication compliance
- MPR (Medical Possession Ratio) = the number of doses taken 
divided by the number of doses prescribed
- Mean MPR over a period of time ~ Probability of being poorly or 
highly compliant
- A threshold of 80% is most commonly used to define high 
compliance 
 Medication persistence
- Continuous variable = the number of days
- Dichotomous variable measured at the end of a predefined time 
period (e.g. 12 months)
- Which threshold regarding discontinuation period?
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Measurement
Osterberg et al. N Engl J Med 2005;353:487–97
Cramer et al. Value Health 2008;11:44-47
 Direct assessment methods (observation, serum drug 
concentration, biochemical analysis…)
- High validity but costly and inconvenient 
 Indirect assessment methods (e.g. retrospective prescription 
claims databases)
- Lack the details of daily dosing (e.g. missing doses, wrong 
timing) => may overestimate adherence
- Inexpensive
- Often the only source available to assess compliance 
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Measurement
« The clinical and economic burden of poor adherence with
osteoporosis medications in Ireland »
What is already know on this topic
- Compliance and persistence with osteoporosis medications are poor 
and suboptimal
- Poor therapeutic adherence results in increased fracture rates
Objectives
- To assess compliance and persistence to OP medications in Ireland
- To quantify the clinical and economic effects of poor adherence
- To estimate the potential cost-effectiveness of hypothetical 
adherence-enhancing interventions 
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Measurement
1. Compliance and persistence data
- Irish HSE-PCRS pharmacy claims database 
- Years 2006-2009
- Aged over 55 years
- New users of anti-osteoporosis medications 
Men Women
55-64 y 1,864 10,075
65-69 y 1,410 8,092
70-74 y 2,667 16,124
75+ y 6,672 36,378
Total 12,613 70,669
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Follow-up 6 month 1 year 1.5 years 2 years 2.5 years 3 years
Women
Non-persistence 26.2% 35.7% 41.9% 47.3% 51.9% 55.0%
Poor compliance 13.1% 7.7% 5.9% 4.7% 4.1% 3.5%
High compliance 60.8% 56.6% 52.2% 48.0% 43.9% 41.5%
N persistent cases 52,192 42,819 35,925 30,051 24,983 20,781
Men
Non-persistence 40.0% 51.8% 58.9% 64.0% 68.1% 70.6%
Poor compliance 10.0% 5.1% 3.4% 2.6% 2.3% 2.1%
High compliance 50.0% 43.2% 37.7% 33.5% 29.6% 27.3%
N persistent cases 7,569 5,557 4,246 3,323 2,567 1,991
*Refill gap period of 9 weeks; MPR ≥80% to define high compliance, <80% to define poor adherence
Table Persistence and compliance data in Irish women and men
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BC base-case
Table Non-persistent patients according to different refill gap periods
Follow-up 6 month 1 year 1.5 years 2 years 2.5 years 3 years
Women
5 weeks 31.4% 43.2% 51.1% 59.2% 64.6% 67.8%
9 weeks (BC) 26.2% 35.7% 41.9% 47.3% 51.9% 55.0%
13 weeks 22.5% 31.0% 36.7% 41.5% 45.8% 48.8%
Men
5 weeks 45.4% 58.2% 66.1% 72.3% 76.5% 78.9%
9 weeks (BC) 40.0% 51.8% 58.9% 64.0% 68.1% 70.6%
13 weeks 36.7% 47.7% 54.9% 59.9% 64.1% 66.7%
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BC base-case
Table Compliance data according to MPR thresholds*
Follow-up 6 month 1 year 1.5 years 2 years 2.5 years 3 years
Women
MPR 70% 91.1% 93.5% 94.4% 95.0% 95.3% 95.6%
MPR 80% (BC) 82.3% 88.1% 89.9% 91.1% 91.2% 92.2%
MPR 90% 76.2% 73.3% 75.1% 75.5% 76.4% 77.5%
Men
MPR 70% 91.9% 95.0% 95.8% 95.9% 96.2% 96.6%
MPR 80% (BC) 83.3% 89.5% 91.7% 92.7% 92.7% 93.0%
MPR 90% 75.8% 74.1% 76.2% 76.8% 77.4% 78.6%
* Percentage of compliant patients among those who are persistent
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Measurement
2. Simulation modelling
- Hiligsmann et al. Value in Health 2009;12:687-96
- Updated version: Hiligsmann et al. Pharmacoeconomics, 2011
Outcomes




- Full adherence (over 3 years)
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Markov microsimulation model (TreeAge Pro 2011)
No Fx
Death
Wrist Fx Other Fx
CV FxHip Fx
Post OtherPost Wrist





CV clinical vertebral. Transitions to death and from post-fracture states to any fractures states, ‘Death’
and ‘No Fx’ were excluded from the graph for simplicity
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55-59 0.76 2.18 6.30 3.68
60-64 1.12 1.75 3.28 2.55
65-69 1.99 2.81 4.42 4.98
70-74 4.73 6.67 7.75 6.77
75-79 9.80 8.32 7.73 13.07
80-84 17.47 9.42 9.78 15.40
+ 85 32.97 14.63 12.36 35.10
Men
55-59 0.39 0.55 0.69 4.40
60-64 0.62 1.97 1.22 2.31
65-69 1.51 1.81 2.11 5.56
70-74 2.02 3.38 0.60 5.18
75-79 5.68 5.61 1.59 6.91
80-84 10.69 6.56 1.82 22.47
+ 85 20.01 14.13 3.82 28.67
Hip fractures (Health 
Atlas Ireland, 2008)
Non-hip fractures
Increased risk with 
osteoporosis
Increased risk when 
new fractures occur during 
the simulation
Mortality rates (Central 
Statistics office in Ireland )
Excess mortality 
after hip and CV 
fractures
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Table Cost (€2008) of fractures at the sites shown by age in Ireland
Healthcare payer
Hip fractures 
(Hospitalisation cost: Health 
Atlas Ireland, 2008)
Non-hip fractures
Long-term cost for 
hip fractures
- Admissions to nursing 
home









50-54 10,920 1899 1582 1896
55-59 11,215 1950 1624 1947
60-64 11,421 1986 1654 1983
65-69 12,168 2116 1762 2112
70-74 12,607 2193 1826 2189
75-79 12,710 2210 1841 2206
80-84 13,140 2285 1903 2281
+ 85 13,099 2278 1897 2274
Men
50-54 10,788 1876 1562 1873
55-59 12,053 2096 1746 2093
60-64 12,890 2242 1867 2238
65-69 14,043 2442 2034 2438
70-74 13,182 2293 1909 2288
75-79 13,460 2341 1949 2337
80-84 13,384 2328 1938 2324
+ 85 13,396 2330 1940 2326
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Women 0.83 (60-69 y), 0.77 (70-79 y) and 0.72 (80-105 y)
Men 0.84 (60-69 y), 0.78 (70-79 y) and 0.71 (80-105 y)
Multipliers for the proportionate effect of a fracture on utility
Hip (1st year / subs years) 0.80 / 0.90
CV (1st year / subs years) 0.72 / 0.93
Wrist (1st year / subs years) 0.94 / 1.00
Other (1st year / subs years) 0.91 / 1.00
Hiligsmann et al. Calcif Tissue Int 2008;82:288-92
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Measurement
Drug therapy
- Oral bisphosphonates (>80%)
Efficacy
- NICE meta-analysis
- Hip (-29%), Vertebral (-42%), Wrist and Other (-22%)
- Linear decrease after stopping therapy
Costs
- Mean drug cost for patients taking OP medications: €422 (Women) & 
€417 (Men) HSE-PCRS database
- Monitoring cost: one yearly physician visit (€65) & one densitometry 
every second year (€90) Irish Osteoporosis Society
No adverse events
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Measurement
Incoporating persistence and compliance in modelling
Persistence
- At risk of discontinuation within 3 years
- Treatment effect reduced by half in the dropout cycle
- For those who early discontinued, no treatment effect + specific cost
- Patients who discontinued therapy can restart therapy after one cycle 
without treatment (re-initiation rates at one year: 25.4% women and 
21.5% in men)
Compliance
- Relative risks from the NICE meta-analysis for compliant patients
- Lower efficacy for poorly compliance (RR=1.17) (Huybrechts et al. 2007)
- Drug costs adjusted by mean MPR in the group
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Measurement
Analyses and simulation
- Patients stratified into groups according to sex (female/male) and 
age (55–64 years, 65–69 years, 70–74 years, and 75+ years)
- Monte-Carlo microsimulations: 200,000 trials and 10 samples
Hiligsmann et al. Pharmacoeconomics, 2011
Model validation
- Absolute lifetime 
risks of fractures
- Tests on parameters
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Measurement
Results Base-case analysis
Follow-up Adherence scenario Incremental values
No Treat RW Full RW vs No 
Treat
Full vs No 
Treat
Full vs RW
Patient cost over lifetime
Treatment cost 0 922 1395 922 1395 473
Disease cost 11,425 10,769 10,284 -656 -1140 -485
Total cost 11,425 11,691 11,679 266 255 -12
Lifetime number of fractures per patient
Hip 0.495 0.475 0.460 -0.020 -0.035 0.015
Overall 1.320 1.269 1.229 -0.052 -0.092 -0.040
QALYs per patient 6.638 6,661 6.678 0.023 0.040 0.017
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Measurement
Results Impact of poor adherence on effectiveness and costs
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Measurement
Results Cost-effectiveness plane. The incremental cost-effectiveness ratio is 
represented by the slope of the line from the origin
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Measurement
Results Number (95% confidence interval) of hip and of all osteoporotic 
fractures due to poor adherence, according to sex and age groups
55-64 y 65-69 y 70-74 y + 75y Total
Hip fractures
Women 41 (36-46) 71 (67-74) 231 (221-242) 752 (722-781) 1094 (1064-1125)
Men 8 (7-9) 10 (9-11) 37 (36-38) 121 (117-126) 177 (172-181)
Total 49 (44-53) 81 (77-84) 268 (258-279) 873 (842-904) 1271 (1238-1304)
All osteoporotic fractures
Women 149 (141-156) 236 (230-242) 655 (638-671) 1774 (1735-1831) 2814 (2771-2856)
Men 32 (30-33) 34 (33-35) 95 (93-96) 366 (359-374) 527 (519-535)
Total 180 (173-188) 270 (263-277) 749 (732-767) 2140 (2100-2181) 3340 (3295-3386)
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Measurement
Results Sensitivity analyses on the clinical burden (expressed in % of QALY 
gain and in number of osteoporotic fractures) of poor adherence with 
osteoporosis medications 
% of QALY gain Number of fractures
Base-case analysis 56.3 (54.5-57.5) 3,340 (3,295-3,386)
Women 57.6 (56.2-59.1) 2,814 (2,771-2,856)
Men 44.7 (42.6-46.8) 527 (519-535)
5-week refill gap 50.9 (49.1-52.7) 3,779 (3,741-3,818)
13-week refill gap 59.9 (58.2-61.6) 3,062 (3,033-3,092)
Full compliance 59.7 (58.2-61.2) 3,191 (3,152-3,229)
MPR of 90% 54.7 (53.3-56.1) 3,612 (3,579-3,645)
MPR of 70% 58.0 (56.9-59.2) 3,266 (3,239-3,294)
Treatment efficacy +20% 58.0 (56.9-59.1) 3,985 (3,952-4,017)
Fracture risk +25% 54.5 (52.7-56.3) 4,342 (4,295-4,388)
Fracture risk -25% 57.4 (56.1-58.5) 2,405 (2,375-2,435)
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Measurement
Results Cost-effectiveness (expressed in cost (in €) per QALY gained) 
between adherence scenarios according to age and sex
RW vs No Treat Full vs No Treat Full vs RW
Women
55-64 y 69,704 57,033 40,574
65-69 y 29,127 18,579 5,465
70-74 y 10,221 4,313 -3,635
+ 75 y 1,823 -2,111 -7,587
Total 10,253 4,878 -2,437
Men
55-64 y 78,409 56,438 38,899
65-69 y 46,183 35,013 25,514
70-74 y 27,921 15,750 6,514
+ 75 y 15,661 8,932 3,393
Total 26,159 16,625 8,916
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Measurement
Results Cost-effectiveness (expressed in cost (in €) per QALY gained) of 
hypothetical adherence-enhancing interventions according to their cost and 
effect on adherence. The cost-effectiveness is graphically presented by the black 
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Cost (in €) per QALY gained
Adherence i mprovement of 10%
Adherence i mprovement of 25%
Adherence i mprovement of 50%
A 25% adherence 
improvement:  
- 50€ per year: 
€11,511/QALY (95% CI 
€9,238-€13,784)
- 100€ per year: 
€54,182/QALY €50 and 
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Measurement
Results Sensitivity analyses on the cost-effectiveness (expressed in cost (in 
€) per QALY gained) of adherence-enhancing interventions 
Adherence improvement
10% 25% 50%
€100 per year of treatment
Base-case 128,621 54,182 26,999
Men 128,898 60,914 35,509
Women 128,574 52,951 25,482
+75 years 110,509 41,859 18,549
One-shot cost
€100 32,906 -5,686 -15,571
€200 95,245 19,790 -4,394
€300 157,565 45,266 7,445
€400 216,894 70,741 18,953
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Measurement
Discussion – Key findings
- Approximately 50% of the benefits of osteoporosis medications are 
lost due to poor compliance and persistence
- More than 90% resulting from non-persistence
- Poor adherence with osteoporosis medications results in a doubling 
of the cost per QALY gained from these medications
- Impact of definitions for persistence and compliance
- Programs to improve adherence have the potential to be an 
attractive approach to improve the allocation of resources
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Measurement
Discussion – Limitations
- Underestimation of the burden of poor adherence (prescription refill
rates + primary adherence not included)
- Highly compliant patients achieved reductions in fracture risk based 
on meta-analysis from published clinical trials
- Modelling assumptions (non-hip fracture data)
- Impact of poor compliance on fracture efficacy not available in 
Ireland
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Discussion – Implications
- Poor adherence = the critical hurdle to osteoporosis management
- Improving adherence is urgently needed BUT complex
- Systematic review (ISPOR special interest group): most effective 
interventions are the monitoring of patients by nursing staff and 
patient education 
- New therapies with longer dosing regimens
⇒ Importance of understanding patient’s preferences for osteoporosis 
treatments and of developing strategies to improve adherence (e.g. 
involving patients into clinical decision-making) – Postdoctoral project
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Discussion – Implications
- Persistence and compliance = important determinants of cost-
effectiveness analyses
- Not only in osteoporosis but many chronic diseases
⇒ Persistence and compliance should be an integral part of 
pharmacoeconomic analyses
- Lack of inclusion could bias the results and lead to suboptimal 
allocation of resources (Hiligsmann et al. Pharmacoeconomics, 2011)
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Discussion – Implications
- Some challenges: improving definitions and measurement, 
epidemiologic survey (treatment-specific), efficacy and 
effectiveness data for high compliance, real-life effectiveness 
and adherence data…
- To assess the cost-effectiveness of specific adherence-
enhancing programs
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Thank you for your attention
